These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 33012873)

  • 21. Asenapine-Induced Acute Dystonia in an Adolescent Male.
    Bhuyan D; Ghosh S; Bhattacharya A; Praharaj SK
    J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):955-956. PubMed ID: 27154343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study.
    Kinoshita T; Bai YM; Kim JH; Miyake M; Oshima N
    Psychopharmacology (Berl); 2016 Jul; 233(14):2663-74. PubMed ID: 27271087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania.
    Tarazi FI; Shahid M
    Drugs Today (Barc); 2009 Dec; 45(12):865-76. PubMed ID: 20135021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of single-administration of D-sorbitol pretreatment on the bitterness and continued willingness to take asenapine: a randomized, single-blind, placebo-controlled, crossover trial.
    Wada S; Iwamoto K; Okumura H; Hida H; Hiraoka S; Kamei A; Mori D; Yamada K; Ando M; Ozaki N; Ikeda M
    BMC Psychiatry; 2024 Jan; 24(1):81. PubMed ID: 38291403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asenapine.
    Weber J; McCormack PL
    CNS Drugs; 2009 Sep; 23(9):781-92. PubMed ID: 19689168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real-world data.
    Takekita Y; Hiraoka S; Iwama Y; Matsui D; Aoki N; Ogata H; Funatsuki T; Shimizu T; Murase Y; Koshikawa Y; Kato M; Kinoshita T
    Neuropsychopharmacol Rep; 2024 Mar; 44(1):234-239. PubMed ID: 37926930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asenapine.
    Meltzer HY; Dritselis A; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2009 Nov; 8(11):843-4. PubMed ID: 19876039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder.
    McIntyre RS
    Expert Rev Neurother; 2010 May; 10(5):645-9. PubMed ID: 20420486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects.
    Gerrits M; de Greef R; Peeters P
    Biopharm Drug Dispos; 2010 Jul; 31(5-6):351-7. PubMed ID: 20549835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
    Citrome L
    Postgrad Med; 2011 Mar; 123(2):153-62. PubMed ID: 21474903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice.
    Fagiolini A; Forgione RN; Morana B; Maccari M; Goracci A; Bossini L; Pellegrini F; Cuomo A; Casamassima F
    Expert Opin Pharmacother; 2013 Mar; 14(4):489-504. PubMed ID: 23356509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania.
    Tarazi FI; Neill JC
    Expert Opin Drug Discov; 2013 Jan; 8(1):93-103. PubMed ID: 23121334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Asenapine review, part II: clinical efficacy, safety and tolerability.
    Citrome L
    Expert Opin Drug Saf; 2014 Jun; 13(6):803-30. PubMed ID: 24793161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Review of Asenapine in the Treatment of Bipolar Disorder.
    Vieta E; Montes JM
    Clin Drug Investig; 2018 Feb; 38(2):87-99. PubMed ID: 29067671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACS chemical neuroscience molecule spotlight on Saphris.
    Hopkins CR
    ACS Chem Neurosci; 2010 Apr; 1(4):263-4. PubMed ID: 22778826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensory evaluation of the bitterness of asenapine using D-sorbitol pretreatment: single-blind, placebo-controlled, crossover trial.
    Wada S; Iwamoto K; Okumura H; Hida H; Hiraoka S; Kamei A; Mori D; Yamada K; Ozaki N
    BMC Psychiatry; 2023 Mar; 23(1):159. PubMed ID: 36918838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.
    Frånberg O; Wiker C; Marcus MM; Konradsson A; Jardemark K; Schilström B; Shahid M; Wong EH; Svensson TH
    Psychopharmacology (Berl); 2008 Feb; 196(3):417-29. PubMed ID: 17940749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iloperidone, asenapine and lurasidone: a primer on their current status.
    Tarazi FI; Stahl SM
    Expert Opin Pharmacother; 2012 Sep; 13(13):1911-22. PubMed ID: 22849428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment.
    Kane JM; Mackle M; Snow-Adami L; Zhao J; Szegedi A; Panagides J
    J Clin Psychiatry; 2011 Mar; 72(3):349-55. PubMed ID: 21367356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.